Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CP-945, 598 · 6 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| CP-945,598 | EXPERIMENTAL | - |
| Mild hepatic function | EXPERIMENTAL | - |
| Moderate hepatic function | EXPERIMENTAL | - |
| Normal hepatic function | EXPERIMENTAL | - |
| Normal renal function | EXPERIMENTAL | - |
| Severe renal impairment | EXPERIMENTAL | - |
| CP-945,598 with Grapefruit Juice | EXPERIMENTAL | CP-945,598 with Grapefruit Juice |
| CP-945,598 alone | EXPERIMENTAL | CP-945,598 alone |
| Group A | EXPERIMENTAL | - |
| Group B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CP-945,598 | DRUG | - |
| sibutramine | DRUG | - |
Inclusion Criteria: * Male and/or female subjects without clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12 lead ECG and clinical laboratory tests * Body Mass Index (BMI) ³30 and \<40 kg/m...
Top 20 of 32 competitors
CP-945,598 is an investigational small molecule being studied for the treatment of obesity. It is a metabolic therapeutic developed by Pfizer, Inc. The drug has been evaluated in clinical trials involving participants with obesity, and it remains in clinical development as an investigational agent.
CP-945,598 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer has conducted multiple clinical trials of this investigational small molecule for obesity, including studies in the United States.
CP-945,598 is in Phase 2 clinical development for obesity. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy. The drug is not yet available to patients outside of clinical research.
CP-945,598 has been studied in six clinical trials, all of which are completed. These include Phase 1 studies such as NCT00472836, NCT00644839, NCT00645021, and NCT00645463, which examined the drug's safety, tolerability, and pharmacokinetics in participants with obesity, including those with renal or hepatic impairment.
CP-945,598 has been evaluated in randomized, double-blind, controlled clinical trials. The studies were designed to compare the investigational drug against a control, and they included healthy volunteers as well as participants with obesity. All six trials of CP-945,598 have been completed.